<DOC>
	<DOC>NCT02187783</DOC>
	<brief_summary>The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.</brief_summary>
	<brief_title>LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)</brief_title>
	<detailed_description />
	<criteria>Patient has a confirmed diagnosis of a select solid tumor (except breast cancer (however, triple negative will be included), liposarcoma, CRPC, melanoma and teratoma) or hematological malignancy (except mantle cell lymphoma). Patient must have been preidentified as having a tumor with CDK4 amplification or mutation, CDK6 amplification or mutation, Cyclin D1 (CCND1) amplification, Cyclin D3 (CCND3) amplification, or p16 (CDKN2A) mutation Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission. Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Patients has received prior treatment with LEE011. Patient has clinically significant resting bradycardia (heart rate &lt; 50 at rest), tachycardia (heart rate &gt; 90 at rest), PR interval &gt; 220 msec, QRS interval &gt; 109 msec, or QTcF &gt; 450 msec. Patients has primary CNS tumor or CNS tumor involvement Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid malignancy,</keyword>
	<keyword>Hematologic malignancy,</keyword>
	<keyword>Mutations,</keyword>
	<keyword>Amplifications,</keyword>
	<keyword>Signature,</keyword>
	<keyword>CDK4,</keyword>
	<keyword>CDK6,</keyword>
	<keyword>CDK4/6,</keyword>
	<keyword>Cyclin D1,</keyword>
	<keyword>CCND1,</keyword>
	<keyword>Cyclin D3,</keyword>
	<keyword>CCND3,</keyword>
	<keyword>p16 mutation,</keyword>
	<keyword>CDKN2A,</keyword>
	<keyword>LEE011,</keyword>
	<keyword>Breast cancer,</keyword>
	<keyword>Ovarian cancer,</keyword>
	<keyword>Lymphoma,</keyword>
	<keyword>Mesothelioma,</keyword>
	<keyword>Pancreatic neuroendocrine,</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Tumor</keyword>
</DOC>